Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $20.25.

Several analysts have commented on the stock. Robert W. Baird upped their target price on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, April 27th. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. reiterated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 21st. Finally, Chardan Capital upped their target price on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $12.11 on Friday. The firm has a fifty day moving average of $13.60 and a two-hundred day moving average of $12.30. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -3.42 and a beta of 1.92. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11. The company had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the previous year, the company posted ($1.10) EPS. As a group, research analysts forecast that Intellia Therapeutics will post -3.18 EPS for the current fiscal year.

Institutional Trading of Intellia Therapeutics

Large investors have recently made changes to their positions in the company. Farallon Capital Management LLC bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $10,486,000. Vanguard Group Inc. increased its holdings in Intellia Therapeutics by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock worth $190,744,000 after purchasing an additional 192,651 shares in the last quarter. Jupiter Asset Management Ltd. bought a new position in Intellia Therapeutics during the 3rd quarter worth about $23,519,000. Contrarius Group Holdings Ltd increased its holdings in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after purchasing an additional 4,337,428 shares in the last quarter. Finally, Canal Insurance CO bought a new position in Intellia Therapeutics during the 4th quarter worth about $899,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.